Recent data suggest that the type of anesthesia used during the resection of solid tumors impacts the long-term survival of patients favoring total-intravenous-anesthesia (TIVA) over inhalative-anesthesia (INHA). Here we sought to query this impact on survival in patients undergoing resection of glioblastoma (GBM). All patients receiving elective resection of a newly diagnosed, isocitrate-dehydrogenase-1-(IDH1)-wildtype GBM under general anesthesia between January 2010 and June 2017 in the Department of Neurosurgery, Heidelberg University Hospital, were included. Patients were grouped according to the applied anesthetic technique. To adjust for potential prognostic confounders, patients were matched in a 1:2 ratio (TIVA vs. INHA), taking into account the known prognostic factors: age, extent of resection, O-6-methylguanine-DNA-methyltransferase-(MGMT)-promoter-methylation-status, pre-operative Karnofsky-performance-index and adjuvant radio- and chemotherapy. The primary endpoint was progression-free-survival (PFS) and the secondary endpoint was overall-survival (OS). In the study period, 576 patients underwent resection of a newly diagnosed, IDH-wildtype GBM. Patients with incomplete follow-up-data, on palliative treatment, having emergency or awake surgery; 54 patients remained in the TIVA-group and 417 in the INHA-group. After matching, 52 patients remained in the TIVA-group and 92 in the INHA-group. Median PFS was 6 months in both groups. The median OS was 13.5 months in the TIVA-group and 13.0 months in the INHA-group. No significant survival differences associated with the type of anesthesia were found either before or after adjustment for known prognostic factors. This retrospective study supports the notion that the current anesthetic approaches employed during the resection of IDH-wildtype GBM do not impact patient survival.

最近的数据表明，实体瘤切除过程中使用的麻醉类型会影响患者的长期生存率，这些患者偏爱全静脉麻醉 (TIVA) 而不是吸入麻醉 (INHA)。在这里，我们试图询问这种对接受胶质母细胞瘤 (GBM) 切除术患者生存率的影响。所有在 2010 年 1 月至 2017 年 6 月期间在海德堡大学医院神经外科接受全麻下新诊断的异柠檬酸-脱氢酶-1-(IDH1)-野生型 GBM 的选择性切除的患者均被纳入研究。根据应用的麻醉技术对患者进行分组。为了调整潜在的预后混杂因素，考虑到已知的预后因素：年龄、切除范围、O-6-甲基鸟嘌呤-DNA-甲基转移酶-(MGMT)-启动子-甲基化状态、术前卡诺夫斯基性能指数和辅助放疗和化疗。主要终点是无进展生存期（PFS），次要终点是总生存期（OS）。在研究期间，576 名患者接受了新诊断的 IDH 野生型 GBM 切除术。随访数据不完整、接受姑息治疗、急诊或清醒手术的患者；TIVA 组有 54 名患者，INHA 组有 417 名患者。匹配后，TIVA 组有 52 名患者，INHA 组有 92 名患者。两组的中位 PFS 均为 6 个月。TIVA 组的中位 OS 为 13.5 个月，INHA 组为 13.0 个月。在调整已知预后因素之前或之后，未发现与麻醉类型相关的显着生存差异。这项回顾性研究支持目前在 IDH 野生型 GBM 切除过程中采用的麻醉方法不会影响患者生存的观点。